Clene Inc. (CLNN) investor relations documents from the company's IR site: 1 presentation; latest deck 2025-12-03. Read in-app with summaries. First-party data.
CLNN Biomarker and Survival Evidence 20251203.pdf: Clene reports statistically significant reductions in ALS biomarkers NfL and GFAP for CNM-Au8, supporting a potential accelerated approval pathway.
| Published | Type | Document |
|---|---|---|
| 2025-12-03 | Presentation | CLNN Biomarker and Survival Evidence 20251203.pdf |
CLNN overview · CLNN earnings · CLNN financials · CLNN KPIs · CLNN ownership · CLNN peers · CLNN filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.